5.09
price up icon8.07%   0.38
 
loading
I Mab Adr stock is traded at $5.09, with a volume of 3.48M. It is up +8.07% in the last 24 hours and up +144.71% over the past month. I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
See More
Previous Close:
$4.71
Open:
$4.75
24h Volume:
3.48M
Relative Volume:
1.92
Market Cap:
$415.65M
Revenue:
$3.91M
Net Income/Loss:
$-206.53M
P/E Ratio:
-2.0504
EPS:
-2.4825
Net Cash Flow:
$-167.78M
1W Performance:
+4.52%
1M Performance:
+144.71%
6M Performance:
+424.74%
1Y Performance:
+324.17%
1-Day Range:
Value
$4.74
$5.64
1-Week Range:
Value
$4.13
$5.64
52-Week Range:
Value
$0.595
$5.90

I Mab Adr Stock (IMAB) Company Profile

Name
Name
I Mab Adr
Name
Phone
-
Name
Address
-
Name
Employee
32
Name
Twitter
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
IMAB's Discussions on Twitter

Compare IMAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IMAB
I Mab Adr
5.09 415.65M 3.91M -206.53M -167.78M -2.4825
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

I Mab Adr Stock (IMAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-09-21 Initiated Siebert Williams Shank Buy
Jun-02-21 Initiated Daiwa Securities Buy
Mar-15-21 Initiated Needham Buy
Mar-03-21 Reiterated H.C. Wainwright Buy
Feb-25-21 Initiated Piper Sandler Overweight
Dec-07-20 Initiated H.C. Wainwright Buy
Jul-27-20 Initiated Cantor Fitzgerald Overweight
Feb-12-20 Initiated China Renaissance Buy
Feb-11-20 Initiated Jefferies Buy
View All

I Mab Adr Stock (IMAB) Latest News

pulisher
Aug 21, 2025

I-Mab’s Q2 2025: Clinical Progress and Financial Strength - TipRanks

Aug 21, 2025
pulisher
Aug 20, 2025

I-Mab ADR (IMAB) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com

Aug 20, 2025
pulisher
Aug 14, 2025

Kimball Electronics Posts Better-Than-Expected Earnings, Joins Terawulf, Dlocal, Equinox Gold And Other Big Stocks Moving Higher On Thursday - Benzinga

Aug 14, 2025
pulisher
Aug 12, 2025

The Psychology of I-Mab ADR Inc. (IMAB) Price Performance: Understanding Market Sentiment - investchronicle.com

Aug 12, 2025
pulisher
Aug 12, 2025

I-Mab (NASDAQ:IMAB) Trading 14.1% Higher – Here’s Why - Defense World

Aug 12, 2025
pulisher
Aug 11, 2025

I-Mab completes enrollment for givastomig trial ahead of schedule By Investing.com - Investing.com South Africa

Aug 11, 2025
pulisher
Aug 11, 2025

I-Mab completes enrollment for givastomig trial ahead of schedule - Investing.com

Aug 11, 2025
pulisher
Aug 08, 2025

Adverse Reactions to Tremelimumab, Durvalumab in Liver Cancer - BIOENGINEER.ORG

Aug 08, 2025
pulisher
Aug 05, 2025

Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System. - Physician's Weekly

Aug 05, 2025
pulisher
Aug 04, 2025

I-Mab ADR: Analyzing IMAB Stock Trends - investchronicle.com

Aug 04, 2025
pulisher
Aug 01, 2025

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares - GlobeNewswire Inc.

Aug 01, 2025
pulisher
Jul 29, 2025

I-Mab ADR (IMAB) Stock: Navigating a Year of Stock Volatility - investchronicle.com

Jul 29, 2025
pulisher
Jul 17, 2025

I-Mab acquires Bridge Health to strengthen givastomig development By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

I-Mab acquires Bridge Health to strengthen givastomig development - Investing.com India

Jul 17, 2025
pulisher
Jul 16, 2025

Best Income Stocks to Buy for July 16th - The Globe and Mail

Jul 16, 2025
pulisher
Jul 11, 2025

I-MAB files 6-K to amend US$21M ADS shelf registration | BQ SEC FilingForm 6-K - Stock Titan

Jul 11, 2025
pulisher
Jul 02, 2025

I-Mab reports 83% response rate for givastomig in gastric cancer study - Investing.com India

Jul 02, 2025
pulisher
Jun 30, 2025

I-Mab’s givastomig shows promising results in gastric cancer study - Investing.com

Jun 30, 2025
pulisher
Jun 27, 2025

I-Mab stock maintains buy rating at H.C. Wainwright on strong cancer data - Investing.com

Jun 27, 2025
pulisher
Jun 26, 2025

I-Mab reports 71% response rate for gastric cancer drug in trial - Investing.com

Jun 26, 2025
pulisher
Jun 24, 2025

H.C. Wainwright reiterates buy rating on I-Mab stock ahead of key data By Investing.com - Investing.com South Africa

Jun 24, 2025
pulisher
Jun 24, 2025

H.C. Wainwright reiterates buy rating on I-Mab stock ahead of key data - Investing.com

Jun 24, 2025
pulisher
Jun 17, 2025

I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Market Momentum: Abpro Holdings Inc (ABP) Registers a 3.72 Increase, Closing at 0.22 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Unity Software Inc’s Market Journey: Closing Strong at 24.40, Up 3.13 - DWinneX

Jun 17, 2025
pulisher
Jun 13, 2025

I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

I-Mab regains Nasdaq compliance as shares maintain $1 minimum bid - Investing.com India

Jun 12, 2025
pulisher
Jun 12, 2025

I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance

Jun 12, 2025
pulisher
Jun 11, 2025

Figure 1. Protein and mRNA expressions of P-glycoprotein in BEL-7402... - researchgate.net

Jun 11, 2025
pulisher
Jun 11, 2025

Willdan Group, Inc.'s (NASDAQ:WLDN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Can This Unstoppable Stock Join Microsoft, Nvidia, Apple, Amazon, Alphabet, Meta Platforms, and Tesla in the $1 Trillion Club? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

Graphjet Technology Discloses Notice from Nasdaq - Yahoo Finance

Jun 10, 2025
pulisher
Jun 07, 2025

B. Riley Financial granted extension from Nasdaq regarding listing rules - Yahoo Finance

Jun 07, 2025
pulisher
Jun 06, 2025

I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy? - sharewise

Jun 06, 2025
pulisher
Jun 06, 2025

All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy - Yahoo Finance

Jun 06, 2025
pulisher
Jun 05, 2025

Asian Stocks Shine As Biotech And Financials Lead Gains - Finimize

Jun 05, 2025
pulisher
Jun 05, 2025

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - Yahoo Finance

Jun 05, 2025
pulisher
Jun 03, 2025

I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series - Yahoo Finance

Jun 03, 2025
pulisher
May 28, 2025

I-Mab stock surges on Lucid Capital’s buy rating initiation By Investing.com - Investing.com South Africa

May 28, 2025
pulisher
May 28, 2025

I-Mab stock surges on Lucid Capital’s buy rating initiation - Investing.com

May 28, 2025
pulisher
May 28, 2025

Lucid Capital sets I-Mab stock Buy rating, $5 target on cancer drug potential - Investing.com

May 28, 2025
pulisher
May 17, 2025

I-Mab’s Financial Report Highlights Givastomig Progress - TipRanks

May 17, 2025
pulisher
May 15, 2025

I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

May 15, 2025
pulisher
May 06, 2025

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 - Barchart.com

May 06, 2025
pulisher
May 05, 2025

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC - Barchart.com

May 05, 2025
pulisher
Apr 14, 2025

After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance

Apr 14, 2025
pulisher
Apr 11, 2025

After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance

Apr 11, 2025
pulisher
Apr 07, 2025

I-Mab at Needham Conference: Strategic Transformation Unveiled - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

I-Mab at Needham Conference: Strategic Transformation Unveiled By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 04, 2025

I-Mab’s Transformative Year: Financial and Strategic Highlights - TipRanks

Apr 04, 2025

I Mab Adr Stock (IMAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):